Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;129(3):314-317.
doi: 10.1111/bju.15664. Epub 2021 Dec 13.

The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography

Hans Veerman  1   2   3 , Maarten Donswijk  4 , Elise Bekers  5 , Judith Olde Heuvel  4 , Yves J L Bodar  2   3 , Thierry N Boellaard  6 , Maurits L van Montfoort  5 , R Jeroen A van Moorselaar  2   3 , Daniela E Oprea-Lager  7 , Pim J van Leeuwen  1   3 , André N Vis  2   3 , Henk G van der Poel  1   2   3
Affiliations

The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography

Hans Veerman et al. BJU Int. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Perera M, Papa N, Roberts M et al. Gallium‐68 prostate‐specific membrane antigen positron emission tomography in advanced prostate cancer – updated diagnostic utility, sensitivity, specificity, and distribution of prostate‐specific membrane antigen‐avid lesions: a systematic review and meta‐analysis. Eur Urol 2020; 77: 403–17 - PubMed
    1. Ceci F, Oprea‐Lager DE, Emmett L et al. E‐PSMA: the EANM standardized reporting guidelines v1.0 for PSMA‐PET. Eur J Nucl Med Mol Imaging 2021; 48: 1626–38 - PMC - PubMed
    1. Paschalis A, Sheehan B, Riisnaes R et al. Prostate‐specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol 2019; 76: 469–78 - PMC - PubMed
    1. Turkbey B, Rosenkrantz AB, Haider MA et al. Update of Prostate Imaging Reporting and Data System version 2. Eur Urol 2019; 76: 340–51 - PubMed
    1. Donato P, Morton A, Yaxley J et al. 68Ga‐PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is 68Ga‐PSMA PET/CT guided biopsy the future? Eur J Nucl Med Mol Imaging 2020; 47: 1843–51 - PubMed

MeSH terms

Substances